NTRA Latest Press Releases

-- February 6, 2026 --

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes Business Wire 6:00 AM

-- February 2, 2026 --

Natera Submits Signatera CDx PMA to FDA Business Wire 6:00 AM

-- January 28, 2026 --

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation Business Wire 8:00 AM

-- January 26, 2026 --

Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care Business Wire 6:00 AM

-- January 21, 2026 --

Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer Business Wire 6:00 AM

-- January 20, 2026 --

Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting Business Wire 6:00 AM

-- January 13, 2026 --

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling Business Wire 8:00 AM

-- January 12, 2026 --

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA Business Wire 10:00 AM

-- January 11, 2026 --

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth Business Wire 10:48 PM

-- January 8, 2026 --

Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial Business Wire 4:01 PM

-- January 7, 2026 --

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Business Wire 8:00 AM

-- January 5, 2026 --

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI Business Wire 7:25 PM

Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology Business Wire 7:00 AM

-- December 18, 2025 --

Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer Business Wire 8:00 AM

-- December 16, 2025 --

I-SPY 2 Publication in Nature Communications Shows Signatera Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer Business Wire 8:00 AM

-- December 12, 2025 --

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer Business Wire 8:00 AM

-- December 10, 2025 --

Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer Business Wire 7:57 PM

-- December 9, 2025 --

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting Business Wire 8:00 AM

-- December 5, 2025 --

Natera Acquires Foresight Diagnostics Business Wire 7:00 AM

-- December 3, 2025 --

New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting Business Wire 8:00 AM

-- December 2, 2025 --

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium Business Wire 8:00 AM

-- November 19, 2025 --

Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month Business Wire 8:00 AM

-- November 12, 2025 --

Natera Integrates with Flatiron Health's OncoEMR Platform Business Wire 8:00 AM

-- November 6, 2025 --

Natera Reports Third Quarter 2025 Financial Results Business Wire 4:05 PM

-- October 31, 2025 --

Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT Business Wire 7:00 AM

-- October 30, 2025 --

Natera to Report its Third Quarter Results on November 6, 2025 Business Wire 7:00 AM

-- October 28, 2025 --

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity Business Wire 7:00 AM

-- October 27, 2025 --

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights Business Wire 6:20 AM

-- October 20, 2025 --

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients Business Wire 1:05 AM

-- October 16, 2025 --

Natera Named to Fast Company's Next Big Things in Tech List Business Wire 8:00 AM

-- October 13, 2025 --

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings Business Wire 8:00 AM

-- October 12, 2025 --

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium Business Wire 6:10 PM

-- October 1, 2025 --

Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT Business Wire 8:00 AM

-- September 30, 2025 --

Natera Announces Publication of Signatera Validation Study in Testicular Cancer Business Wire 8:00 AM

-- September 29, 2025 --

Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows Business Wire 8:00 AM